Page 66 - Sohini Das

PE firm Multiples picks up 9.3% stake in BDR Pharma for Rs 685 cr

Multiples is the first private equity (PE) investor in BDR Pharma

Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line

Biological E slashes Corbevax prices by 70% to Rs 250 a dose for pvt mkt

End user would now need to pay Rs 400 per jab including the administration charge to get the shot at a private vaccination centre; move aimed at benefiting children

Biological E plans to ramp up non-vaccines business in next three years

The privately held company has a turnover of about Rs 1,000 crore, of which close to 70-80 per cent come from the vaccines business now

AXA set to launch mental health insurance in Indian group policies

The first-ever standalone product in this space will provide Rs 25,000 for virtual consultations with therapists, psychologists and life coaches, and up to Rs 1 lakh for hospitalisation

USFDA rush after 2-year lull: 20-30% new products may be open to inspection

The last two years saw limited physical inspections due to travel restrictions during the pandemic

Analgesics, other common drugs used during Covid-19 clock double-digit CAGR

Pain and fever drug Paracetamol and blood-clot preventing Enoxaparin both post growth rates beyond 20%

Cipla looks to invest more in mRNA tech; holds discussions with firms

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the commercial growth engines

Cipla will use Covid-19 bulk drugs inventory when demand rises

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

PAG invests Rs 2,000 crore in Optimus Drugs for controlling stake

Exact stake size not revealed, sources put the number at 70%

Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

CEPI funds Bharat Biotech consortium project for variant-proof Covid-19 jab

CEPI has till date announced funding for nine such projects including the Bharat Biotech one

Submit data on vaccine immunity among young children: NTAGI to institutes

The National Technical Advisory Group on Immunisation (NTAGI) will hold its crucial meeting on vaccine for children next week

Coronavirus: Decoding India's 'excess mortality' according to WHO estimates

A Business Standard analysis found that most of the countries with an older cohort of population and higher in the development index had a lower excess mortality rate than India.

Nearly one-fourth of all men and women in India are now obese: NFHS

Obesity a growing concern, especially in urban India; marginal decline in stunting among children

Fertility rate drops to 2 children; now below replacement level: NFHS

The TFR ranges from 1.1 children per woman in Sikkim to 3 children per woman in Bihar

India Covid death toll highest in world, says WHO as govt rejects report

India's official Covid death toll is 481,486 between January 1, 2020, and December 31, 2021

Govt data shows surge in people dying without any medical attention in 2020

Fewer women gave birth in institutional settings amid pandemic

Biological E eyes 1 billion doses of non-Covid vaccines in 5 years

At present, the firm has a capacity to make 1.5-2 billion Covid vaccines and 600 million non-Covid vaccines per annum.